Cart
Oops, your cart is still empty
Looks like you haven’t added anything yet. Start exploring our products and find what you need.
Tesamorelin vs Ipamorelin: A Complete Research Comparison
These materials are research-grade reference compounds sold for laboratory research use only. They are not for human or veterinary use.
Tesamorelin and ipamorelin are studied together often enough that researchers new to the growth-hormone-axis literature sometimes assume they are variations on one theme. They are not. They represent the two distinct classes of growth-hormone secretagogue: tesamorelin is an analog of growth-hormone-releasing hormone, and ipamorelin is a growth-hormone-releasing peptide that acts at the ghrelin receptor. The comparison is therefore a comparison of two mechanisms, not two versions of one.
This article sets out the differences in detail and strictly in research terms: identity and structure, the two receptor systems, what the literature reports in animal and cell models, and how each compound is verified and handled. Every finding is framed within its experimental context, and nothing here is guidance for human or veterinary use.
At a Glance
- Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (a modified GHRH(1-44) sequence), studied at the GHRH receptor.
- Ipamorelin is a synthetic pentapeptide studied at the ghrelin receptor (GHS-R1a).
- They are the two principal secretagogue classes: GHRH analogs and GHRPs.
- Tesamorelin is based on a natural releasing hormone; ipamorelin is a fully designed molecule noted for selectivity.
- Both are research chemicals for laboratory use only, verified per lot by HPLC and mass spectrometry.
Quick Comparison
| Attribute | Tesamorelin | Ipamorelin |
|---|---|---|
| Peptide class | GHRH analog | Growth-hormone-releasing peptide (GHRP) |
| Receptor studied | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Structure | Modified GHRH(1-44) analog with an N-terminal stabilizing group | Synthetic pentapeptide (5 residues) |
| Basis | Endogenous releasing hormone | Fully designed molecule |
| Noted feature | Stabilized GHRH sequence | Selectivity in its original characterization |
| Verification | HPLC + mass spectrometry, per-lot COA | HPLC + mass spectrometry, per-lot COA |
What Tesamorelin Is
Tesamorelin is a modified analog of growth-hormone-releasing hormone based on the GHRH(1-44) sequence, carrying an N-terminal modification that is associated in the literature with improved stability relative to unmodified GHRH. Because it is built on the natural releasing hormone, tesamorelin is studied at the GHRH receptor and is, in effect, a stabilized way of probing GHRH-receptor biology in research systems. Exact molecular weight and purity for any lot are documented on the Certificate of Analysis.
What Ipamorelin Is
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) from the growth-hormone-releasing peptide class. It was characterized as the first selective growth-hormone secretagogue, meaning it produced a comparatively narrow response in the models used (Raun et al., 1998). Unlike tesamorelin, it does not derive from a natural hormone; its non-natural residues are design features studied for their effect on receptor interaction and stability.
Two Secretagogue Classes
The growth-hormone secretagogues divide into two families defined by receptor. GHRH analogs, such as tesamorelin, act at the GHRH receptor. Growth-hormone-releasing peptides, such as ipamorelin, act at the ghrelin/growth-hormone-secretagogue receptor, GHS-R1a. The GHRP series was historically central to the discovery of that receptor and its natural ligand, ghrelin (Bowers, 2012; Kojima et al., 1999). Because the two families engage different receptors, they are frequently studied together to examine both arms of the axis.
What the Research Literature Reports
Ipamorelin
Its founding report described selective secretagogue activity in animal models (Raun et al., 1998), and the broader ghrelin-receptor literature supplies the pharmacological framework for the class (Bowers, 2012). Research focuses on receptor binding, downstream signaling, and selectivity.
Tesamorelin
Tesamorelin is studied as a stabilized GHRH analog engaging the GHRH receptor, with research interest in how the stabilizing modification affects the molecule’s behavior relative to native GHRH in research systems. As with ipamorelin, these are mechanistic and model-level observations, not statements about human outcomes.
Structure, Stability, and Research Handling
The two differ sharply in size and design: a modified 44-residue GHRH analog versus a five-residue synthetic peptide. That difference carries into their handling and stability profiles, with the smaller designed peptide and the larger fragment presenting different considerations. General peptide-stability principles apply to both, and lot-specific stability is documented on the Certificate of Analysis rather than stated as a blanket duration.
How Researchers Choose Between Them
Selection depends on which receptor system the study targets. Work on the GHRH-receptor arm points to a GHRH analog such as tesamorelin; work on the ghrelin-receptor arm points to a GHRP such as ipamorelin. Peptide size, stability, selectivity, and the depth of prior literature for the model of interest all factor in. The two are often paired precisely because their mechanisms are complementary.
Chemical Identity and Verification
Both are verified by mass spectrometry for identity and HPLC for purity, with results on a lot-specific Certificate of Analysis. Net peptide content is distinct from chromatographic purity. Reconcile every molecular figure against the COA before use.
Storage and Handling in a Laboratory Context
Store sealed material cold, shield it from light, and avoid repeated freeze-thaw. Lyophilized material is generally more stable than material in solution. Lot-specific stability is documented on the COA.
Research Limitations and Open Questions
The secretagogue literature is built largely on animal and cell models, and findings there do not translate directly to any human context. Direct, identical-condition comparisons of a specific GHRH analog against a specific GHRP are relatively uncommon, so cross-study conclusions should be drawn carefully.
Frequently Asked Questions
What is the main difference between tesamorelin and ipamorelin?
They act on different receptors. Tesamorelin is a GHRH analog at the GHRH receptor; ipamorelin is a GHRP at the ghrelin receptor. That is the fundamental distinction.
What are the two secretagogue classes?
GHRH analogs (such as tesamorelin, sermorelin, and CJC-1295) and growth-hormone-releasing peptides (such as ipamorelin, GHRP-6, and hexarelin).
What makes tesamorelin different from plain GHRH?
It is a modified GHRH analog carrying an N-terminal stabilizing group, studied for improved stability relative to the unmodified sequence.
Why is ipamorelin called selective?
In its original characterization it produced a comparatively narrow secretagogue response in the models tested (Raun et al., 1998).
Why are they studied together?
Because GHRH analogs and GHRPs engage two complementary receptor systems, so pairing them lets researchers examine both arms of the growth-hormone axis.
How is each verified for identity and purity?
By mass spectrometry for identity and HPLC for purity, documented on a lot-specific Certificate of Analysis.
Do these findings apply to people?
No. All cited work is in animal or cell models and describes mechanism and research outcomes only.
Related Reading
- Tesamorelin reference page
- Ipamorelin reference page
- Growth-Hormone Secretagogue Research Peptides (class overview)
- Lab Reports
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID 9849822.
- Bowers CY. History to the discovery of ghrelin. Methods Enzymol. 2012. PMID 22975043.
- Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999. PMID 10604470.
Research-use notice: Tesamorelin and ipamorelin are research chemicals sold for laboratory research use only. They are not for human or veterinary use. Every finding is reported in the specific research context of the cited study.
